Chief Financial Officer · Camp4 Therapeutics Corp (CAMP)

Kelly Gold

A named executive officer of Camp4 Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,846,733

FY2024: $1,310,523

Compensation figures as of the proxy filed April 23, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Kelly Gold compensation by year

Camp4 Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Camp4 Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$433,333$465,000
Bonus—$0
Stock awards—$0
Option awards$404,991$1,112,042
Non-equity incentive$138,500$178,095
Pension and deferred compensation—$0
All other$333,699$91,596
Total$1,310,523$1,846,733

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Camp4 Therapeutics Corp DEF 14A filed April 23, 2026, accession 0001736730-26-000026, and prior-year filings. Open the filing on EDGAR.

$1.3M
$1.8M
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU6,060$10,000—
Option88,581—$12.79
Option65,001—$3.86
Option17,334—$8.41
Option25,071—$9.08
Option190,000—$6.01
Option918—$5.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Camp4 Therapeutics Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed April 23, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-31Purchase—10,000$3.9610,000
2026-08-03Purchase—6,551$1.6574,428

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Camp4 Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Josh Mandel-BrehmPresident and Chief Executive Officer$3,327,238
Kelly Gold · this pageChief Financial Officer$1,846,733
Yuri MaricichChief Medical Officer$1,814,042

The full Camp4 Therapeutics compensation record

free company brief

This page is one person within Camp4 Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Camp4 Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Camp4 Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy